The Food and Drug Administration has granted full approval to Novavax, Inc. (NASDAQ:NVAX) COVID-19 vaccine, but with notable ...

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to ...

China on Sunday announced anti-dumping duties as high as 74.9% on imports of POM copolymers, a type of engineering plastic, ...

COVID-19 vaccine in a letter to the company dated Friday. “Under this license, you are authorized to manufacture ...

The U.S. Food and Drug Administration ((FDA)) on Saturday approved the COVID-19 vaccine developed by Gaithersburg, Maryland-based biotech Novavax (NASDAQ:NVAX). Accordingly, the protein-based shot, ...

Novavax (NasdaqGS:NVAX) recently reported a significant financial turnaround for Q1 2025, demonstrating substantial revenue growth and net income improvements. The amending of its collaboration ...

This was the stock's second consecutive day of losses.

Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...

QBTS: D-Wave Quantum shares are rallying after the company beat analysts' estimates and reported record quarterly revenue ...

Shares of Novavax Inc. NVAX shed 2.37% to $6.19 Tuesday, on what proved to be an all-around mixed trading session for the ...

BofA Securities 2025 Health Care Conference May 14, 2025 6:00 PM ETCompany ParticipantsJohn Jacobs - President and CEOJim ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.